Navigation Links
Avanir Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
Date:5/31/2011

ALISO VIEJO, Calif., May 31, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the Jefferies 2011 Global Healthcare Conference in New York, NY.

  • Location: Grand Hyatt, New York, NY
  • Presentation date: Tuesday June 7, 2011
  • Presentation time: 12:15 p.m. Eastern Time

A live webcast and 30-day archive of this presentation will be available at http://www.avanir.com.

About Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

AVANIR™ is a trademark owned by Avanir Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners

©2011 Avanir Pharmaceuticals, Inc. All Rights Reserved.


'/>"/>
SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. AVANIR to Present at the Wedbush Life Sciences Conference
2. AVANIR to Present at the Canaccord Genuity Growth Conference
3. AVANIR Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
5. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
8. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
9. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
10. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
11. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , ... April 18, 2017 , ... A number of ... This webinar, which is part of the Protein and Cell Analysis Education Webinar ... outline where this technology fits in current and future applications. , Many flow ...
(Date:4/19/2017)... ... April 19, 2017 , ... Nobilis Therapeutics Announces Completion of Landmark ... Clinical Data in its Upcoming Post Traumatic Stress Disorder Trial , Nobilis Therapeutics, ... trial assessing efficacy of its NBTX-001, a xenon-based therapeutic in the treatment of Panic ...
(Date:4/19/2017)... ... April 19, 2017 , ... As part of the ... to novices as well as experienced users, attendees will gain a better understanding ... tests. , Hemostasis testing quality is determined by preanalytical variables which encompass ...
(Date:4/19/2017)... and WESTMINSTER, Colo. ... LLC ("Oxford"), an industry-leading specialty finance firm that ... services companies, today announced the closing of a ... Inc. ("Cerapedics") a privately-held orthobiologics company engaged in ... products for the treatment of orthopedic injuries. ...
Breaking Biology Technology:
(Date:4/11/2017)... , Apr. 11, 2017 Research and ... Market 2017-2021" report to their offering. ... The global eye tracking market to grow at a ... report, Global Eye Tracking Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
Breaking Biology News(10 mins):